Landos Biopharma, Inc. (LABP)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Gregory Oakes | President, CEO & Director | 1.05M | -- | 1969 |
| Dr. Fabio Cataldi M.D. | Executive VP & Chief Medical Officer | 732.29k | -- | 1968 |
| Ms. Jennifer Creel | Interim Chief Financial Officer | -- | -- | 1971 |
| Ms. Rebecca Mosig Ph.D. | Vice President of Corporate Development | -- | -- | -- |
| Dr. Josep Bassaganya-Riera DVM, Ph.D. | Advisor | 1.79M | -- | 1975 |
Landos Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 19
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Corporate Governance
Recent Events
- Apr 16, 202410-K/A: Periodic Financial ReportsSee Full Filing
- Apr 15, 2024PREM14A: Proxy StatementsSee Full Filing
- Mar 26, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 25, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 21, 2024S-8: Offering RegistrationsSee Full Filing